Women's Experience With Bremelanotide for Low Sexual Desire: Increased Desire and Physical Arousal
Exit surveys and interviews from RECONNECT trials confirmed bremelanotide-treated premenopausal women with HSDD experienced increased sexual desire and physical arousal that placebo-treated women did not, validating the clinical trial primary findings from the patient perspective.
Quick Facts
What This Study Found
From 242 exit surveys and 80 telephone interviews, bremelanotide-treated women described increased sexual desire, physical arousal, and improved sexual activity quality — physiological responses not reported by placebo-treated women, who described non-physiological benefits only.
Key Numbers
242 exit surveys; 80 phone interviews; bremelanotide users reported desire, arousal, relationship quality improvements; placebo users reported communication benefits only
How They Did This
Post-trial qualitative study from RECONNECT Phase 3 trials (NCT02333071, NCT02338960). 242 quantitative exit surveys (17 questions) and 80 qualitative telephone interviews (17 questions). Participants blinded to treatment assignment during assessment.
Why This Research Matters
HSDD significantly impacts women's quality of life and relationships. Patient-reported outcomes confirming real physiological improvements — beyond placebo effects — validate bremelanotide as a genuine treatment, not just a psychological intervention.
The Bigger Picture
Sexual health pharmacotherapy has been controversial, with debates about whether treatments provide genuine physiological benefits or just placebo effects. This patient perspective data clearly separates bremelanotide's physiological effects from placebo's psychological ones.
What This Study Doesn't Tell Us
Post-hoc qualitative analysis from a clinical trial population. Self-reported outcomes subject to recall and reporting bias. Limited to premenopausal women. Only 80 completed interviews. Cultural factors may influence reporting.
Questions This Raises
- ?How do bremelanotide's subjective effects compare between different doses?
- ?Do the patient-reported benefits persist with long-term use?
- ?Would similar patient perspective assessments be valuable for other sexual health treatments?
Trust & Context
- Key Stat:
- Real physiological effects Women on bremelanotide reported physical arousal and desire that placebo-treated women did not — confirming the drug produces genuine physiological changes beyond placebo expectations
- Evidence Grade:
- Moderate evidence: large qualitative dataset (242 surveys, 80 interviews) from blinded Phase 3 trial participants. Confirms primary trial findings from patient perspective.
- Study Age:
- Published 2021. Bremelanotide (Vyleesi) was approved in 2019 and is commercially available.
- Original Title:
- The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
- Published In:
- Journal of women's health (2002), 30(4), 587-595 (2021)
- Authors:
- Koochaki, Patricia, Revicki, Dennis, Wilson, Hilary, Pokrzywinski, Robin, Jordan, Robert, Lucas, Johna, Williams, Laura A, Sadiq, Amama, Krop, Julie
- Database ID:
- RPEP-05507
Evidence Hierarchy
Frequently Asked Questions
What does bremelanotide (Vyleesi) actually feel like?
Women in this study described bremelanotide as producing increased feelings of sexual desire, physical arousal, and improved overall quality of sexual activities. These were physiological experiences — increased body sensations and desire — not just improved mood or relationship communication.
Is bremelanotide better than placebo?
Yes — this study clearly separated bremelanotide's effects from placebo. Women on the drug reported specific physiological improvements (desire, arousal) that placebo users did not experience. Placebo users reported only non-physiological benefits like better partner communication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05507APA
Koochaki, Patricia; Revicki, Dennis; Wilson, Hilary; Pokrzywinski, Robin; Jordan, Robert; Lucas, Johna; Williams, Laura A; Sadiq, Amama; Krop, Julie. (2021). The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.. Journal of women's health (2002), 30(4), 587-595. https://doi.org/10.1089/jwh.2020.8460
MLA
Koochaki, Patricia, et al. "The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.." Journal of women's health (2002), 2021. https://doi.org/10.1089/jwh.2020.8460
RethinkPeptides
RethinkPeptides Research Database. "The Patient Experience of Premenopausal Women Treated with B..." RPEP-05507. Retrieved from https://rethinkpeptides.com/research/koochaki-2021-the-patient-experience-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.